임상 한눈에 보기

• 28건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 1, Phase 2 · Phase 1 · N/A · Phase 2
• Status: Active, not recruiting · Recruiting · Not yet recruiting
• 주요 endpoint: Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events · Long term tolerability and safety of Temferon as determined by the incidence of adverse events · Proportion of patients achieving haematologic recovery by Day +30 (defined as the first of at least 3 consecutive days with a neutrophil count >0.5 x 10^9/L and platelet count >20 x 10^9/L) · Determine the maximum tolerated dose of Temferon · Identify presence of transduced myeloid cells in bone marrow as determined by vector copy number
• 등록된 결과: ORR 0%
• 핵심: Background: Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The ce…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.